Biotech Flow Pharma, Inc. Announces Formation of China Joint Venture With Investing Partner Button Capital
Tuesday, September 25, 2018 1:14 PM
Anhui Province-based Button Capital Makes Seed Round Investment in Hefei Sageland Biotechnology Limited, Which Will Assist with Funding and Management of Flow Pharma's China-based Clinical Trial Operations
NEWARK, CA / ACCESSWIRE / September 25, 2018 / Flow Pharma, Inc. a San Francisco Bay Area based biotechnology company with its FlowVax peptide vaccine platform technology, announces formation of its Hefei Sageland Biotechnology Limited joint venture with Button Capital in China. ''Button Capital is a cross-border investment and consulting company based in China's Anhui Province. With this investment into Flow Pharma's Wholly Foreign-Owned Enterprise (WFOE), we are happy to be working with the Company as they prepare to begin clinical trials in China,'' said Shutian Liu, Managing Director Button Capital.
''We are in China continuing to establish collaborations with senior researchers at tier-one institutions to manufacture and test our FlowVax vaccines directed against neoantigens expressed on cancer cells. We are working with the best physicians and scientists in the field. Our newly formed JV will enable us to contract with, and help fund, manufacturing and testing activities needed for clinical trials in China,'' said Lu Wang, Ph.D., General Manager and Director of Hefei Sageland Biotechnology Limited.
''Therapeutic cancer vaccines targeting neoantigens can potentially kill cancer cells very selectively while avoiding making the patient sick. Flow Pharma is utilizing Artificial Intelligence (''AI'') augmented techniques to find cancer neoantigens most susceptible to attack by the patient's immune system. We plan to use our synthetic peptide vaccine platform to create an injection that can be given to the patient, directing their own white blood cells to attack their cancer,'' said C.V. Herst, Ph.D., Chief Science Officer.
''Teaching a cancer patient's killer T-Cells to attack and kill cancer cells, by injecting the patient with a therapeutic cancer vaccine, is an exciting opportunity. China is an interesting place to conduct cancer clinical trials because patients requiring specialty care go to local centers of excellence simplifying recruitment, while allowing the study to be conducted at tier-one facilities with world-class principal investigators. We welcome Button Capital as a founding partner joining us to form our joint venture in China,'' said Flow Pharma CEO Reid Rubsamen, M.D.
Flow Pharma, Inc. is preparing to test therapeutic cancer vaccines targeting neoantigens found in various cancers. Neoantigens are small peptide markers expressed on cancer cells as a result of a cancer-causing viral infection or mutation of the DNA in normal cells that cause transformation into cancer cells.
About Flow Pharma
Flow Pharma, Inc. is a San Francisco Bay Area based, pre-clinical stage biotechnology company using artificial intelligence to guide selection of neoantigen peptide targets on cancer cells or virus-infected cells for attack by the patient's own, native immune system. These peptides can then be loaded into the FlowVax synthetic, therapeutic vaccine platform for administration by injection.
About Button Capital
Button Capital (Button) is a cross-border investment company. Based in Silicon Valley, Button has business operation around the world in US, Europe, China and Israel. Button is focused on bringing innovative life sciences and medical technology to where they are needed. They've built three arms to support their vision. The arm of Investment focuses on facilitating the growth of early stage life sciences ventures and speeding up the growth of industry via cross-border M&A. The arm of Advisory Service to C-Suite focuses on supporting entrepreneurs to explore China market and suggesting strategic buyers to accomplish global M&A. The arm of Button Analytics plays a fundamental role in deal souring and market trend analysis via Button's proprietary data platform.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (''the Company''), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ''believes,'' ''expects,'' ''intends,'' ''plans,'' ''anticipates,'' or ''may,'' and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
Flow Pharma, Inc.
39655 Eureka Drive
Newark, California 94560
SOURCE: Flow Pharma, Inc.